thx yehudi here it is, as supplied by iil this morning...

First 12 Last

Share
Profile

Follow
TitusPullo

4,568 Posts.

31

21/12/16

11:19

Post #: 21482945
Share

Originally posted by yehudi ↑

Bioshares latest edition listed its 6 top picks for 2017.
Opthea was one of them as it was last year. They have arrived at similar conclusions to those outlined by TitusPullo. A brief summary of these conclusions follows: Investors received an early Christmas present when news broke on the failure of Ophthotech Corporation's Fovista in two Phase III trials. The result for Opthea is that it shifts its wet AMD candidate OPT 302 further towards a front row position for new approaches for treating wet AMD. Fovista targets PGDF, a growth factor that is involved in cell migration and blood vessel growth. Fovista is a pegylated aptamer, a single stranded oligo-nucleotide that in theory can bind with high specificity and affinity to its target. One conclusion from the trail failure is that PGDF is not a viable target in diseases with a vascular component. Opthea's clinical program has seen OPT 302 move this year from Phase Ib and into a Phase IIa trial, with results expected in 2017 Q1. Positive results can be expected to cause a rerating of the stock.
Two VEGF-A drugs, Lucentis and Eylea, last year generated sales of over US$7 billion and this excludes the 60% of the market from off-label use of the drug Avastin. However, 50% of patients receiving VEGF-A inhibitors do not achieve significant vision gain, which means an opportunity exists for a combination therapy which could meet that need e.g. OPT302 combined with Lucentis, or indeed an entirely new and yet to be developed approach.

Expand

thx yehudi

here it is, as supplied by iil this morning

http://www.innateimmuno.com/irm/company/showpage.aspx/PDFs/1348_0/BiosharesEdition678TopSixPicks2017

.

OPT Price at posting: 75.0¢ Sentiment: None Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

GRL

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

BTH

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

AN1

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

AUN

Cyclone signs MOU with Vale for development of Iron Bear play

BNL

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

HotCopper Highlights: Your most watched stocks for Week 46, 2024

ME1

Banshee's historic trenches prove rich in antimony and gold for GDM

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

EDE

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

LYN

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

There are more pages in this discussion • 9 more messages in this thread...

First 12 Last

Add OPT (ASX) to my watchlist

(20min delay)
Last 65.5¢		Change -0.045(6.43%)		Mkt cap ! $855.6M

Open	High	Low	Value	Volume
69.5¢	69.5¢	63.0¢	$2.808M	4.305M

Buyers (Bids)

No.	Vol.	Price($)
1	49996	65.5¢

Sellers (Offers)

Price($)	Vol.	No.
66.0¢	50869	6

View Market Depth

No.	Vol.	Price($)
4	45916	0.590
2	37273	0.585
3	38706	0.580
2	108695	0.575
3	44061	0.570

Price($)	Vol.	No.
0.600	10000	1
0.605	47182	2
0.610	42308	4
0.615	1600	1
0.620	130700	4

Last trade - 16.10pm 15/11/2024 (20 minute delay)

OPT (ASX) Chart

thx yehudi here it is, as supplied by iil this morning...

Top Stories

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

Cyclone signs MOU with Vale for development of Iron Bear play

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

HotCopper Highlights: Your most watched stocks for Week 46, 2024

Banshee's historic trenches prove rich in antimony and gold for GDM

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

Buyers (Bids)

Sellers (Offers)